Your browser doesn't support javascript.
loading
A multidisciplinary and structured investigation of three suspected clusters of transverse upper limb reduction defects in France.
Boudet-Berquier, Julie; Demattei, Christophe; Guldner, Laurence; Gallay, Anne; Manouvrier, Sylvie; Botton, Jérémie; Philippat, Claire; Delva, Fleur; Bloch, Juliette; Semaille, Caroline; Odent, Sylvie; Perthus, Isabelle; Randrianaivo, Hanitra; Babajko, Sylvie; Barjat, Tiphaine; Beneteau, Claire; Brennetot, Naima; Garne, Ester; Haddad, Georges; Hocine, Mounia; Lacroix, Isabelle; Leuraud, Klervi; Mench, Michel; Morris, Joan; Patrier, Sophie; Sartelet, Arnaud; Verloes, Alain; Bonaldi, Christophe; Le Barbier, Mélina; Gagnière, Bertrand; Pépin, Philippe; Ollivier, Ronan; Bitoun, Monique; King, Lisa; Guajardo-Villar, Andrea; Gomes, Eugenia; Desenclos, Jean-Claude; Regnault, Nolwenn; Benachi, Alexandra.
Afiliação
  • Boudet-Berquier J; Non-Communicable Diseases and Injuries Department, Santé Publique France, Saint Maurice, France. Julie.BOUDET-BERQUIER2@santepubliquefrance.fr.
  • Demattei C; Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), Centre Hospitalier Universitaire de Nîmes, Nîmes, Languedoc-Roussillon, France.
  • Guldner L; Environment and Work Department, Santé Publique France, Saint Maurice, Health, France.
  • Gallay A; Non-Communicable Diseases and Injuries Department, Santé Publique France, Saint Maurice, France.
  • Manouvrier S; Reference Centre of Developmental Anomalies and Defect Syndromes, RADEME Maladies Rares du Développement Et du Métabolisme, Université Lille, 7364, Lille, EA, France.
  • Botton J; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, Saint-Denis, France.
  • Philippat C; Faculty of Pharmacy, Paris-Saclay University, Orsay, France.
  • Delva F; Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Grenoble Alpes, Grenoble, France.
  • Bloch J; INSERM, BPH, UMR1219, EPICENE Team, University of Bordeaux, Bordeaux, France.
  • Semaille C; Environmental and Occupational Health Department, Bordeaux University Hospital, 33000, Bordeaux, France.
  • Odent S; ANSES, Maisons-Alfort, France.
  • Perthus I; Executive Department, Santé Publique France, Saint-Maurice, France.
  • Randrianaivo H; Reference Centre of Developmental Anomalies and Defect Syndromes, Hôpital Sud, CHU de Rennes, Rennes, France.
  • Babajko S; Auvergne registry of congenital anomalies (CEMC-Auvergne), Department of clinical genetics, Centre de Référence des Maladies Rares, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
  • Barjat T; La Réunion registry of congenital anomalies, Centre Hospitalier Universitaire de La Réunion, Île de la Réunion, France.
  • Beneteau C; Molecular Oral Pathophysiology Laboratory, Centre de Recherche des Cordeliers, INSERM UMRS, Université Paris Cité, Sorbonne Université, 1138, Paris, France.
  • Brennetot N; Fédération Hospitalo-Universitaire DDS-ParisNet, INSERM, Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Garne E; UR2496, Biomedical Research in Odontology, Université Paris Cité, Montrouge, France.
  • Haddad G; Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France.
  • Hocine M; INSERM U1059 SAINBIOSE, Université Jean Monnet, Saint-Étienne, France.
  • Lacroix I; Department of Human Genetics, University Hospital Hôtel Dieu, Nantes, France.
  • Leuraud K; French National Reference for Children Limb Defect, Hôpitaux de Saint-Maurice, Saint Maurice, France.
  • Mench M; Department of Pediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.
  • Morris J; CH Simone Veil, Blois, France.
  • Patrier S; Conservatoire National des Arts et Métiers, Paris, France.
  • Sartelet A; REGARDs Network, Pharmacologie Médicale et Clinique, CERPOP INSERM UMR 1295-SPHERE team, Faculté de Médecine Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • Verloes A; Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.
  • Bonaldi C; INRAE, BIOGECO, UMR 1202, University of Bordeaux, F­33615, Pessac, France.
  • Le Barbier M; Population Health Research Institute, St George's University of London, London, UK.
  • Gagnière B; Department of Pathology, Rouen University Hospital, Rouen, France.
  • Pépin P; Clinical Department of Ruminant, University of Liège, 4000, Liège, Belgium.
  • Ollivier R; Genetics Department, APHP, Robert-Debré University Hospital, Paris, France.
  • Bitoun M; Methodology and Biostatistics Department, Santé Publique France, Saint Maurice, France.
  • King L; Environment and Work Department, Santé Publique France, Saint Maurice, Health, France.
  • Guajardo-Villar A; Cellule Bretagne, Santé Publique France, Rennes, France.
  • Gomes E; Cellule Auvergne-Rhône-Alpes, Santé Publique France, Clermont-Ferrand, France.
  • Desenclos JC; Cellule Pays-de-la Loire, Santé Publique France,, Nantes, France.
  • Regnault N; Cellule Pays-de-la Loire, Santé Publique France,, Nantes, France.
  • Benachi A; Cellule Pays-de-la Loire, Santé Publique France,, Nantes, France.
Eur J Epidemiol ; 39(7): 753-771, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38671254
ABSTRACT

INTRODUCTION:

Between 2019-2021, facing public concern, a scientific expert committee (SEC) reanalysed suspected clusters of transverse upper limb reduction defects (TULRD) in three administrative areas in France, where initial investigations had not identified any risk exposure. We share here the national approach we developed for managing suspicious clusters of the same group of congenital anomalies occurring in several areas.

METHODS:

The SEC analysed the medical records of TURLD suspected cases and performed spatiotemporal analyses on confirmed cases. If the cluster was statistically significant and included at least three cases, the SEC reviewed exposures obtained from questionnaires, environmental databases, and a survey among farmers living near to cases' homes concerning their plant product use.

RESULTS:

After case re-ascertainment, no statistically significant cluster was observed in the first administrative areas. In the second area, a cluster of four children born in two nearby towns over two years was confirmed, but as with the initial investigations, no exposure to a known risk factor explaining the number of cases in excess was identified. In the third area, a cluster including just two cases born the same year in the same town was confirmed.

DISCUSSION:

Our experience highlights that in the event of suspicious clusters occurring in different areas of a country, a coordinated and standardised approach should be preferred.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deformidades Congênitas das Extremidades Superiores Limite: Child / Female / Humans / Infant / Male País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Deformidades Congênitas das Extremidades Superiores Limite: Child / Female / Humans / Infant / Male País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article